After many years of research, AI-supported molecules have started entering clinical trials and the 2024 Nobel Prize in Chemistry recognized the impact of computational biology on reenvisioning the drug discovery process. This opening session will discuss where AI applications are already showing the most utility in biopharma development and how executives should prepare for the next wave of applications for better developing therapies and cures for patients.